InterGenetics

InterGenetics is a biotechnology firm specializing in advanced genetic testing and analysis services to improve understanding of genetic predispositions and health risks for individuals and healthcare providers. Founded in 1999 in Oklahoma City, US, InterGenetics focuses on providing genetic testing solutions. The company has undergone strategic changes since its inception and raised USD 6. 00 mn in May 2005, which is the total amount raised to date.

The founder, Constantinos Pangalos, has a background that includes previous entrepreneurial experience, contributing to the company's vision in the biotechnology space. InterGenetics. com primarily operates in the biotechnology sector, focusing on providing advanced genetic testing and analysis services. The company specializes in products designed to enhance understanding of genetic predispositions and health risks, thereby enabling informed decision-making for individuals and healthcare providers.

These products serve a diverse client base that includes healthcare professionals, genetic counselors, and individuals seeking personalized health insights. The company’s offerings are tailored to address various health concerns, including hereditary conditions and disease risk assessment, and are marketed in specific geographical areas, including North America and Europe, where there is significant demand for genetic testing services. InterGenetics. com generates revenue through a combination of direct-to-consumer sales and partnerships with healthcare providers.

The revenue model encompasses both one-time purchases and subscription services for ongoing genetic analysis and reporting. Clients engage in transactions for specific testing services, with pricing structured according to the complexity and depth of the analysis required. Flagship services may include comprehensive genetic panels that assess multiple health conditions, making the pricing strategy accessible to both individual consumers and healthcare institutions. This dual approach broadens the customer base and enhances the company’s market presence in the competitive biotechnology landscape.

InterGenetics is focused on developing new genetic testing products and enhancing existing offerings, with upcoming launches slated for later in 2023. The company plans to expand its services into additional markets in Asia and Latin America by 2024, targeting regions with growing healthcare demands. The recent funding of USD 6. 00 mn raised in May 2005 will be utilized to support these initiatives, including research and development of new testing technologies and expanding marketing efforts in the new geographic areas.